Cargando…
The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review
BACKGROUND AND OBJECTIVE: Triple negative breast cancer (TNBC) refers to a special subtype of breast cancer that is negative for the estrogen receptor, the progesterone receptors, and human epidermal growth factor receptor 2. As a group of diseases, it has strong heterogeneity. Refractory metastatic...
Autores principales: | Jiang, Meng-Ping, Huang, Xiang, Yin, Yong-Mei, Tang, Jin-Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469164/ https://www.ncbi.nlm.nih.gov/pubmed/36111045 http://dx.doi.org/10.21037/atm-22-3434 |
Ejemplares similares
-
Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021) -
An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023) -
Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors
por: Djomehri, Sabra I., et al.
Publicado: (2020) -
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022) -
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
por: Jiang, Yi-Zhou, et al.
Publicado: (2020)